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Aims Long-term endurance sport practice has been increasingly recognized as a risk factor for lone atrial ﬁbrillation (AF).
However, data on the outcome of circumferential pulmonary vein ablation (CPVA) in endurance athletes are scarce.
The aim of the study was to evaluate the efﬁcacy of CPVA in AF secondary to endurance sport practice.
Methods
and results
Patients submitted to CPVA answered a questionnaire about lifetime history of endurance sport practice. Endurance
athletes were deﬁned as those who engaged in .3 h per week of high-intensity exercise for at least the 10 years
immediately preceding their AF diagnosis. A series of 182 consecutive patients was included (51+11 years, 65%
with paroxysmal AF, 81% men, 42+6 mm mean left atrial diameter); 107 (59%) patients had lone AF, and 42 of
them (23% of the study population) were classiﬁed as endurance athletes (lone AF sport group). Freedom from arrhyth-
mia after a single CPVA was similar in the lone AF sport group compared with the remaining patients (P ¼ 0.446). Left
atrial size and long-standing AF were the only independent predictors for arrhythmia recurrence after ablation.
Conclusion Circumferential pulmonary vein ablation was as effective in AF secondary to endurance sport practice as in other
aetiologies of AF.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Atrial ﬁbrillation (AF) is the most common cardiac rhythm dis-
order in clinical practice. The estimated prevalence of AF is 0.4–
1% in the general population,
1 increasing with age to 8% in those
older than 80 years.
2 The recognized risk factors for developing
AF include age, hypertension, structural heart disease, diabetes
mellitus, and hyperthyroidism.
3 However, in a signiﬁcant number
of patients younger than age 60, no cardiovascular disease or any
other known causal factor is present and the aetiology remains
unclear. This condition is termed lone AF,
4 and may be responsible
for as many as 30% of patients with paroxysmal AF seeking medical
attention.
5,6 In recent years, long-term endurance sport practice
has been recognized as a risk factor for AF.
7–14 On the other
hand, AF ablation has emerged as an effective and safe invasive
treatment of drug-refractory AF.
15–21 However, little is known
about the outcome of this therapy in AF secondary to endurance
sport practice.
22 The aim of the present study was to analyse the
efﬁcacy of circumferential pulmonary vein ablation (CPVA) in
endurance athletes with lone AF referred to AF ablation.
Methods
Study population
A series of 182 consecutive patients submitted to a ﬁrst CPVA
procedure because of symptomatic and drug-refractory AF between
February 2003 and October 2006 was included in the study. Patients
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rence of AF episodes.
Prior to the procedure, all patients underwent transthoracic echo-
cardiography to rule out structural heart disease and to measure the
cardiac chambers and left ventricular ejection fraction. Transoesopha-
geal echocardiography was performed 1–5 days before ablation to
exclude the presence of intracavitary thrombus, as was magnetic res-
onance angiography of the left atrium (LA) and pulmonary veins
(PVs) which, when possible, merged into the navigation system to
achieve better spatial resolution and anatomical deﬁnition.
Anti-arrhythmicdrugtherapywasstoppedatleastﬁvehalf-livesbefore
the ablation, except in patients receiving amiodarone, to try to unmask
the potential triggers of AF, such as supraventricular tachycardias (AV
nodal re-entry or accessory pathway-mediated atrioventricular recipro-
cating tachycardia). Patients on oral anticoagulation stopped medication
3 days prior to the procedure, and low-molecular-weight heparin was
administered until the day before the ablation. All ablation procedures
were performed by experienced operators. Written informed consent
was obtained from all the participants. The protocol was approved by
the Institutional Ethics Committee.
Deﬁnitions
Atrial ﬁbrillation was classiﬁed as paroxysmal, persistent, or long-
standing,followingthedeﬁnitionestablishedbyAFablationconsensus.
23
Lone AF was deﬁned as AF presenting in individuals younger than
60 years without clinical or echocardiographic evidence of cardiopul-
monary disease, including hypertension, or other identiﬁable cause
for the arrhythmia such as hyperthyroidism or alcohol abuse.
4
Athletes were deﬁned as those who performed regular endurance
sport activity (cycling, jogging, swimming, soccer, rowing, etc.) for at
least 3 h per week for at least the 10 years immediately preceding
the arrhythmia diagnosis. This cut-off point was chosen because it rep-
resents a lifetime sport practice of at least 1500 h, which, as previously
described,
8 is associated with a higher risk of lone AF.
Vagally induced AF was deﬁned as AF occurring at least 80% of the
time during sleep, after heavy meals or in the hours immediately fol-
lowing exercise. Adrenergically induced AF was deﬁned as AF episodes
that started during waking hours at least 80% of the time and during
strenuous exercise or other states of adrenergic activation.
10,24 The
remaining patients were classiﬁed as having AF of unknown origin.
Circumferential pulmonary vein ablation
Catheters were introduced percutaneously through the femoral vein; a
transseptal puncture was performed to access the LA. After transsep-
tal access, a bolus of heparin was administered (5000–6000 IU,
according to patient weight), followed by additional boluses to main-
tain an activated clotting time of 200–250 s. Ablation was performed
under intravenous sedation with midazolam and analgesia with meper-
idin and phentanyl. Oxygen saturation and invasive arterial blood
pressure were monitored throughout the procedure. A three-
dimensional map was constructed using an electro-anatomical
mapping system (CARTO, Biosense-Webster Waterloo, Belgium or
NAVX, St Jude Corporation, St Paul, MN, USA) to support the cre-
ation and validation of radiofrequency (RF) lesions. Continuous RF
lesions surrounding each ipsilateral PV were delivered as described
previously.
25 Ablation lines were also deployed along the LA roof
and LA posterior wall joining contralateral encircling lesions, and
along the mitral isthmus. Mitral isthmus ablation was performed in all
patients by creating an RF line from the inferior-lateral aspect of the
left PV lesions to the mitral annulus. This line was anatomically per-
formed, and no electrical block was assessed. Then, an RF line was
created connecting contralateral PV-encircling lesions through the
LA roof, and the LA posterior wall was electrically excluded by
adding another ablation line, on top of the roof line, connecting the
inferior aspect of the contralateral PV. The isolation of the posterior
wall was conﬁrmed by the absence of electrical activity and the inability
to capture with pacing inside the whole encircled LA posterior region.
All patients got ablation lines, regardless of AF type.
Radiofrequency was delivered through an 8 mm or irrigated tip
thermocouple-equipped catheter, using a target temperature of
558C at a maximum output of 60 W for the 8 mm tip catheter and
488C at 40 W for the irrigated tip catheter.
The endpoint was a reduction of local electrogram to ,0.15 mV.
19
Follow-up
Patients were followed up at the outpatient clinic at 1, 4, and 7 months
after the ablation procedure and every 6 months thereafter. Routine
24 or 48 h Holter monitoring was performed before each appoint-
ment, and a 12-lead electrocardiogram was obtained at each visit.
Patients were asked to report to the emergency room or our arrhyth-
mia unit for an ECG if any symptom suggestive of recurrence occurred
between scheduled visits.
After the ablation procedure, all patients received anti-arrhythmic
treatment for at least 1 month to protect against early recurrences
and continued oral anticoagulation for a minimum of 2 months to
maintain an international normalized ratio between 2.0 and 3.0.
Additionally, magnetic resonance angiography was repeated at 3–6
months after the procedure to evaluate the presence of PV stenosis.
Arrhythmia recurrence was deﬁned as a documented AF or atrial
ﬂutter episode of .30 s. Arrhythmic episodes within the ﬁrst
3 months after the CPVA (healing period) were not considered in
the evaluation of ﬁnal success rates because they are often described
as transient recurrences related to atrial inﬂammatory processes
following RF lesions.
26
The endpoint of the study was freedom from arrhythmia recurrence
after a single CPVA procedure, without anti-arrhythmic medication.
A minimum follow-up of 3 months was required.
Statistical analysis
Continuous variables were expressed as mean+SD. Comparisons
were made using Student’s t-test or x
2 analysis as appropriate. The
relationship between baseline variables and time to recurrence
during follow-up was evaluated using survival Cox analysis method-
ology; relationships with P , 0.10 were included as covariates in the
multivariable analysis. Predictors of arrhythmia recurrence were
assessed with a Cox regression model using a backward stepwise pro-
cedure with criteria of P , 0.05 for inclusion and P . 0.10 for removal
from the model. A two-sided P-value  0.05 was considered statisti-
cally signiﬁcant. Analyses were performed using the SPSS 12.0 statisti-
cal package (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
A series of 182 consecutive patients with symptomatic and drug
refractory AF was included in the study. Their baseline character-
istics are shown in Table 1. The majority (81%) of patients were
male, younger than 75 years with a mean age of 51+11 years,
and without a markedly dilated LA. A total of 120 (66%) patients
had paroxysmal AF; AF was persistent in 39 patients (21%), and
the remaining 23 patients (13%) had long-standing AF.
Efﬁcacy of CPVA of AF in endurance athletes 31Lone AF was diagnosed in 107 (58%) patients; 42 of these
patients (23% of the total study population) were identiﬁed as
endurance athletes and included in the lone AF sport group.
The clinical and echocardiographic characteristics of the lone
sport AF group vs. patients with lone AF and no history of endur-
ance sport practice and the remaining patients (the control group)
are given in Table 2. In the lone AF sport group, there was a higher
proportion of male patients, and the left ventricular end-systolic
diameter was smaller than in the control group.
When we analyse baseline characteristics of the lone AF and
lone AF sport groups, there are no statistically signiﬁcant differ-
ences, except for a higher proportion of male patients in the
lone AF sport group (P ¼ 0.031).
Outcomes after circumferential
pulmonary vein ablation
The mean follow-up was 18.69+11.7 months.
Ablation was performed using 35.7+14.8 min of RF with total
ﬂuoroscopic and procedural durations of 26.0+9.3 and 122.3+
33.1 min, respectively. The procedural duration of ablation com-
prised the time between the vascular puncture and the withdrawal
of the catheters (skin-to-skin time). The complications rate in the
lone AF sport group was comparable with the control group (7.1
vs. 4.3%; P ¼ 0.45). Overall, four patients (2.2%) suffered a transi-
ent cerebrovascular ischaemia, which was resolved under heparin
with normal computed tomography scanning; three patients
(1.6%) showed transient inferior myocardial ischaemia during the
procedure, secondary to air embolism, resolved with sublingual
NTG within a few minutes and without consequences; and two
patients (1.1%) had cardiac tamponade during transseptal punc-
ture, resolved by pericardiocentesis.
The probability of remaining free from arrhythmia at 1-year
follow-up after a single CPVA procedure, based on Kaplan–
Meier estimates, was similar in the lone AF sport group and con-
trols: 59 and 48%, respectively, log-rank test P ¼ 0.44 (Figure 1).
On the other hand, the probability of remaining free from arrhyth-
mia at 1-year follow-up after a single CPVA procedure was similar
in the lone AF sport group compared with other patients with lone
AF and no history of endurance sport activity (59 vs. 47%, log-rank
test P ¼ 0.532) (Figure 2).
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Table 2 Clinical and echocardiographic characteristics of control group, lone AF sport group, and patients with lone AF
and no history of endurance sport practice
Control group Athletes (lone AF sport group) Lone AF P-value
a P-value
b
LAD (mm) 41.0+6.2 41.1+4.4 39+6 0.883 0.174
LVEDD (mm) 51.7+5.3 50.0+4.3 51+4.46 0.233 0.288
LVESD (mm) 33.5+6.0 30.4+4.7 32.5+4.37 0.027 0.060
LVEF (%) 60.1+10.6 62.9+8.9 61.7+8.5 0.152 0.610
Age (years) 52.1+10.8 48.5+11.0 47.3+10.5 0.057 0.585
Paroxysmal AF 90 (64%) 31 (74%) 48 (74%) 0.251 0.603
Vagal AF 48 (34%) 16 (38%) 19 (36%) 0.650 0.545
Hypertension 60 (43%) 0 (0%) 0 (0%) ,0.001
Male gender 111 (79%) 39 (93%) 50 (77%) 0.0427 0.031
Structural heart disease 32 (23%) 0 (0%) 0 (0%) ,0.001
AF, atrial ﬁbrillation; LAD, left atrial anteroposterior diameter; LVEDD, left ventricle end-diastolic diameter; LVESD, left ventricle end-systolic diameter; LVEF, left ventricle
ejection fraction.
aP-value: control group vs. lone AF sport group.
bP-value: lone AF sport group vs. lone AF (without history of sport practice) group.
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Table 1 Clinical and echocardiographic parameters at
baseline
Baseline characteristics of patients n 5 182
Age (years) 51+11
Male gender 148 (81%)
Hypertension 59 (32%)
Type of AF
Paroxysmal 120 (66%)
Persistent 39 (21%)
Long-standing 23 (13%)
Structural heart disease 32 (18%)
Lone AF 107 (59%)
Endurance athletes
a 64 (35%)
Lone AF sport group
b 42 (23%)
AF origin
Vagal 64 (35%)
Adrenergic 5 (3%)
Unknown 113 (62%)
AF duration (years) 6.1+5.0
Echocardiography
LAD (mm) 41.0+5.9
LVEDD (mm) 51.4+5.2
LVESD (mm) 32.9+ 5.8
LVEF (%) 60.7+10.3
Data are expressed as mean+SD or number (%) of patients. AF, atrial ﬁbrillation;
LAD, anteroposterior left atrial diameter; LVEDD, left ventricular end-diastolic
diameter; LVEF, left ventricular ejection fraction.
a.3 h/week .10 years when arrhythmia was diagnosed (with or without any
other risk factors for AF).
b.3 h/week .10 years when arrhythmia was diagnosed and without any other
risk factors for AF (i.e. athletes with lone AF).
N. Calvo et al. 32Table 3 shows the relationship between each baseline variable
and arrhythmia recurrence. In the Cox regression multivariable
analysis, after adjusting for the type of AF (paroxysmal, persistent,
or long-standing), age, HTA, LA dimension, EF, LV dimensions,
presence of structural cardiac disease, and regular sport practice,
only LA anteroposterior diameter and long-standing AF were inde-
pendent predictors of arrhythmia recurrence (Table 4). The ejec-
tion fraction was a predictor of AF recurrence in the univariable
analysis. However, it had no independent predictive value for
recurrence in the multivariable analysis.
Ablation was repeated in 67 patients of this series (37%), achiev-
ing a 72% overall probability of freedom from arrhythmia recur-
rence at 1 year without anti-arrhythmic drugs. There were no
statistically signiﬁcant differences in the proportion of redo pro-
cedures between the lone AF sport group (40.5%) and the
control group (37.3%) (P ¼ 0.587) and between the lone AF
(36.4%) and the lone AF sport group (P ¼ 0.540). The majority
of these patients had AF recurrences (62%), atrial ﬂutter was
present in 12%, and the remaining patients had AF and atrial
ﬂutter recurrences (26%). All patients showed reconduction into
the prior PV-encircling areas.
The Kaplan–Meier probability of remaining arrhythmia-free
after repeated ablations was higher in the lone AF sport group
(81%) at 1 year compared with the control group (63%, P ¼
0.051) (Figure 3).
Discussion
The main ﬁnding of the present study is that the probability of
remaining free of arrhythmia recurrences after a single CPVA
Figure 1 Kaplan–Meier curves for long-term freedom from
recurrent arrhythmias after a single ablation procedure in the
lone AF sport group (dashed line) and the control group (solid
line).
Figure 2 Kaplan–Meier curves for long-term freedom from
recurrent arrhythmias after a single ablation procedure in the
lone AF sport group (dashed line) and patients with lone AF
and no history of exercise activity (solid line).
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Table 3 Relationship between each baseline variable
and arrhythmia recurrence after a single ablation
procedure
Hazard ratio (95% CI) P-value
Age (years) 1.004 (0.983–1.025) 0.742
Male gender 1.048 (0.598–1.838) 0.869
Hypertension 1.181 (0.743–1.877) 0.482
Paroxysmal AF 0.535 (0.344–0.831) 0.005
Structural heart disease 0.931 (0.501–1.729) 0.821
AF duration (months) 1.00 (0.997–1.003) 0.940
LAD (mm) 1.057 (1.013–1.104) 0.011
LVEDD (mm) 1.014 (0.962–1.069) 0.609
LVESD (mm) 1.036 (0.997–1.077) 0.070
LVEF (%) 0.974 (0.953–0.996) 0.020
Sport practice 0.821 (0.475–1.419) 0.479
AF, atrial ﬁbrillation; LAD, left atrial anteroposterior diameter; LVEDD, left
ventricle end-diastolic diameter; LVESD, left ventricle end-systolic diameter; LVEF,
left ventricle ejection fraction.
................................................................................
Table 4 Final model of the Cox regression for
arrhythmia recurrence aftera single ablation procedure
Hazard ratio (95% CI) P-value
AF
Paroxysmal 1 (—) —
Persistent 1.819 (0.990–3.340) 0.054
Long-standing 2.297 (1.090–4.839) 0.029
LAD (mm) 1.069 (1.018–1.122) 0.007
Efﬁcacy of CPVA of AF in endurance athletes 33was similar in athletes compared with the control group. Further-
more, LA diameter and long-standing AF were the only indepen-
dent predictors of recurrence.
Recent studies have shown that the prevalence of AF is higher in
individuals who regularly engage in endurance sports than in
control populations.
7–13Additionally, Heidbu ¨chel et al.
27 reported
that a history of endurance sport activity is associated with the
development of AF after ablation of atrial ﬂutter. In contrast
with these previous studies, Pelliccia et al.
28 reported that the inci-
dence of lone AF among competitive athletes was uncommon and
similar to that observed in the general population. However, the
study was performed in young athletes at the moment of highest
activity. Studies supporting the association have been performed
in middle-aged individuals, after many years of sport practice.
The most recent and largest epidemiological study
14 supports
that this association is not a matter of selection because despite
adjustment for multiple potentially confounding lifestyle factors
and health conditions, vigorous exercise activity was associated
with an increased risk of developing AF.
The pathophysiological mechanisms responsible for increased
AF risk in individuals who practice an endurance sport remain
unclear. However, it is well known that the athlete’s heart is
characterized by increased LA size and left ventricular mass, adap-
tations that may create the substrate for developing AF. Another
proposed mechanism is increased vagal tone, resulting in a short
refractory atrial period.
29 Experimental animal models have
demonstrated that AF can be induced by acetylcholine,
30 and
that increasing vagal tone shortens the atrial refractory period,
which, combined with atrial stimulation, induces AF.
31
In the present study, we did not ﬁnd differences in LA or LV size
between the lone AF sport group and the control group. We think
the explanation could be that exercise training leads to LA and LV
enlargement similar to that seen in patients with other causes of
AF, such as increased afterload in hypertension.
It is worth mentioning that our data showed that a high pro-
portion of men with AF submitted to the ablation procedure are
engaged in regular endurance sport practice (35%). This pro-
portion is signiﬁcantly higher than that of males of the same age
in the general population of Catalonia (15.4%), according to the
data from the REGICOR study.
32 This ﬁnding is in agreement
with previous studies
7–14 and further supports the association
between long-term endurance sport practice and AF.
We included highly symptomatic patients younger than 75 years
and without a markedly dilated LA. Therefore, this selection pro-
cedure may explain the high proportion of lone AF among our
patients. Nevertheless, we think that it represents the clinical prac-
tice, as our ﬁndings are consistent with the previous ablation
studies which show that 50–60% of patients do not have structural
heart disease.
33–35
Circumferential pulmonary vein ablation is established as an
effective and safe treatment of AF, with success rates ranging
from 30 to 85%.
20 To date, one small study by Furlanello et al.
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has demonstrated high efﬁcacy of repeated ablation procedures
in a population of elite athletes; however, no data comparing
endurance athletes and a control population are available. Theor-
etically, the effectiveness of this procedure in athletes, who are
usually a younger population, could be associated with higher
success rates than in the general population with AF on the basis
of age. On the other hand, the pathophysiological mechanisms of
AF in endurance athletes could be responsible for reducing the
success of CPVA.
In the present study, we observed no difference in the effective-
ness of CPVA between a population of endurance athletes with
lone AF and other patients with AF after a ﬁrst CPVA procedure,
and found that endurance sport practice is not a predictor of the
results of the ablation procedure.
Data obtained after repeated ablation procedures probably
reﬂect a selection bias and should be interpreted with caution,
since repeated ablation procedures were not performed in
patients with a low probability of success.
Earlier studies reported LA anteroposterior diameter prior to
the ablation procedure, paroxysmal vs. persistent AF, early recur-
rence of AF, age, and hypertension as independent predictors of
AF recurrences.
25,35,36 Our study conﬁrmed LA diameter and long-
standing AF as the most powerful predictors of AF recurrence
after CPVA; in addition, persistent AF showed a trend towards a
higher probability of recurrence (P ¼ 0.054).
Study limitations
One limitation of the study is the follow-up method of scheduled
24 or 48 h Holter recordings. If asymptomatic arrhythmias or non-
documented symptomatic episodes occurred between routine
follow-up visits, recurrence after ablation might have been
missed in these patients, as previous studies have demonstrated.
37
This could have affected athletes differently than the control group,
since athletes are typically well trained in monitoring heart rate and
are more used to detecting pulse abnormalities. Theoretically,
asymptomatic arrhythmia episodes could have been more
Figure 3 Kaplan–Meier curves for long-term freedom from
recurrent arrhythmias after repeated ablation procedures in the
lone AF sport group (dashed line) and the control group (solid
line).
N. Calvo et al. 34frequently detected among athletes. However, this potential bias is
unlikely to be signiﬁcant, since our data showed a trend towards
fewer recurrence episodes among athletes. Another limitation is
that both study groups included endurance athletes because ath-
letes with any other identiﬁed risk factor, such as hypertension,
were included in the control group. However, the main purpose
of the study was to analyse the efﬁcacy of the CPVA in ‘purely’
endurance sport related arrhythmia. Finally, the number of athletes
with lone AF is relatively small. Therefore, further studies including
a larger number of patients are required to conﬁrm our results.
Conclusions
Circumferential pulmonary vein ablation seems to be as effective in
endurance athletes as in other aetiologies of AF.
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Pseudo-atrial ﬁbrillation due to non-reentrant AV nodal tachycardia
Sheldon M. Singh, Conor D. Barrett, and Saumya Das*
The Cardiac Arrhythmia Service, GRB 109, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
* Corresponding author. Tel: þ1 617 726 5067, Fax: þ1 617 726 3852, Email: sdas@partners.org
A 40-year-old man was referred for an atrial ﬁbrillation (AF) ablation. Close examination of his Holter recording was suggestive of
intermittent atrial activity (Panel A). The patient underwent a comprehensive electrophysiology study which demonstrated simul-
taneous fast and slow pathway activation, or ‘one for two’, due to dual AV nodal physiology (Panel B). Slow pathway modiﬁcation
eliminated the tachycardia.
Non-reentrant AV nodal tachycardia is rare, and can be mistaken for AF due to its irregular rhythm with difﬁcult to visualize
P-waves. Careful examination of the surface ECG can avoid an erroneous diagnosis of AF and institution of unnecessary therapy.
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